Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, Reyderman L.
Landry I, et al. Among authors: hall n.
Clin Pharmacol Drug Dev. 2021 Jun;10(6):681-690. doi: 10.1002/cpdd.915. Epub 2021 Jan 17.
Clin Pharmacol Drug Dev. 2021.
PMID: 33455055
Free PMC article.
Clinical Trial.